VivoSeq
Oncology

Refractory Cancer

5

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Refractory Cancer is an early-stage landscape with 5 programs across 8 companies. The most active players are Immatics Biotechnologies GmbH, IGM Biosciences, Inc., Acrotech Biopharma Inc..

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Immatics Biotechnologies GmbH

6 programs

PreclinicalI

IGM Biosciences, Inc.

0 programs

PreclinicalA

Acrotech Biopharma Inc.

0 programs

PreclinicalM

Myriad Therapeutics, Inc.

0 programs

PreclinicalB

BioCryst Pharmaceuticals

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

20

clinical trials

Completed17 · 85%
Terminated2 · 10%
Recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors
Recruiting·IImmatics Biotechnologies GmbH·Preclinical·NCT05958121·400 enrolled
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
Completed·National Cancer Institute (NCI)·Phase 1·NCT03388632·31 enrolled
Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain
Completed·NNYU Langone Health·Phase 1·NCT00025311
Flavopiridol in Treating Patients With Refractory Cancer
Completed·National Cancer Institute (NCI)·Phase 1·NCT00019344
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
Completed·IIGM Biosciences, Inc.·Phase 1·NCT05702424·14 enrolled
Safety Study of MGA271 in Refractory Cancer
Completed·MMacroGenics·Phase 1·NCT01391143·179 enrolled
A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
Completed·IInstitut Curie·Phase 2·NCT01771458·742 enrolled
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Completed·AAcrotech Biopharma Inc.·Phase 1·NCT01222780·22 enrolled
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Completed·SSamsung Medical Center·Phase 1·NCT02630199·65 enrolled
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
Completed·MMacroGenics·Phase 1·NCT02381314·24 enrolled
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Completed·MMacroGenics·Phase 1·NCT02475213·146 enrolled
Perillyl Alcohol in Treating Patients With Refractory Cancer
Completed·National Cancer Institute (NCI)·Phase 1·NCT00002862·25 enrolled
BCX-1777 in Treating Patients With Refractory Cancer
Completed·BBioCryst Pharmaceuticals·Phase 1·NCT00073944
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer
Completed·GSK logoGSK·Phase 1·NCT00504790·39 enrolled
T138067 Sodium in Treating Patients With Advanced Refractory Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003359·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)